SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1 Approval was based on the pivotal Phase 3…
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
calendar_today
June 23, 2026
domain
abbvie